GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortrea Holdings Inc (FRA:K67) » Definitions » ROCE %

Fortrea Holdings (FRA:K67) ROCE % : -4.74% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Fortrea Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Fortrea Holdings's annualized ROCE % for the quarter that ended in Mar. 2024 was -4.74%.


Fortrea Holdings ROCE % Historical Data

The historical data trend for Fortrea Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortrea Holdings ROCE % Chart

Fortrea Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROCE %
- 3.86 6.87 1.95

Fortrea Holdings Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 1.62 4.34 1.88 -0.72 -4.74

Fortrea Holdings ROCE % Calculation

Fortrea Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=65.015/( ( (4047.778 - 659.856) + (3995.552 - 711.5) )/ 2 )
=65.015/( (3387.922+3284.052)/ 2 )
=65.015/3335.987
=1.95 %

Fortrea Holdings's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-152.352/( ( (3995.552 - 711.5) + (3900.984 - 752.836) )/ 2 )
=-152.352/( ( 3284.052 + 3148.148 )/ 2 )
=-152.352/3216.1
=-4.74 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fortrea Holdings  (FRA:K67) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Fortrea Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Fortrea Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Fortrea Holdings (FRA:K67) Business Description

Traded in Other Exchanges
Address
8 Moore Drive, Durham, NC, USA, 27709
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Fortrea Holdings (FRA:K67) Headlines

No Headlines